| Company/Division name | PENDING TARIFFS - Takeda Pharmaceuticals |
| Parent company | PENDING TARIFFS - Takeda Pharmaceuticals |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2025 |
| Year reshoring implemented or to be implemented: | 2030 |
| Capital investment ($): | 30,000 |
| Country(ies) from which reshored: | Japan |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Pharmaceuticals |
| What non-domestic negative factors made offshoring less attractive? | Tariffs |
| What domestic positive factors made reshoring more attractive? | Higher productivity |
